Top Tweets for #Apexigen

over 4 years ago

We are relentlessly committed to leading the charge against #pancreaticcancer w/ @PennCancer, @bmsnews, @CancerResearch, #Apexigen & others. Thank you to all who made the Phase II PRINCE trial possible – we’re one step closer to ending this cancer. https://t.co/qJUEHaNhuD #ASCO22

parkerici's tweet photo. We are relentlessly committed to leading the charge against #pancreaticcancer w/ @PennCancer, @bmsnews, @CancerResearch, #Apexigen & others. Thank you to all who made the Phase II PRINCE trial possible – we’re one step closer to ending this cancer. https://t.co/qJUEHaNhuD #ASCO22 https://t.co/REmQ1HU14V

0

12

2

0

over 4 years ago

It’s an important step in the fight against this deadly #cancer, with partners @PennMedicine, @bmsnews, @CancerResearch, #Apexigen and others.

parkerici's tweet photo. It’s an important step in the fight against this deadly #cancer, with partners @PennMedicine, @bmsnews, @CancerResearch, #Apexigen and others. https://t.co/5WkY1j0zJx

1

3

0

Evaluate Pharma @evaluatepharma

over 4 years ago

On June 3 PICI will present research @ASCO that suggests which patients with #pancreaticcancer are more likely to respond to promising combination therapies. See the abstract here: https://t.co/RHuXAIGm7C #immunotherapy #chemotherapy @CancerResearch @PennCancer @BMSnews #Apexigen

parkerici's tweet photo. On June 3 PICI will present research @ASCO that suggests which patients with #pancreaticcancer are more likely to respond to promising combination therapies. See the abstract here: https://t.co/RHuXAIGm7C #immunotherapy #chemotherapy @CancerResearch @PennCancer @BMSnews #Apexigen https://t.co/PYVkMzV3VC

0

16

7

0

over 4 years ago

Undaunted by the biotech bear market, the US-Chinese oncology group #Apexigen has triggered plans to list via a Spac: https://t.co/tqjRx8NBw8 @evaluatevantage #VantageDaily #EvaluateVantage

evaluatepharma's tweet photo. Undaunted by the biotech bear market, the US-Chinese oncology group #Apexigen has triggered plans to list via a Spac: https://t.co/tqjRx8NBw8

@evaluatevantage #VantageDaily #EvaluateVantage https://t.co/KynoaTvYW9

0

2

0

almost 6 years ago

<10% of adv #pancreaticcancer patients survive 5 years. New Ph1b data in @TheLancetOncol shows a novel chemo + #immunotherapy combo can shrink tumors in patients. Proud to partner with @PennCancer @CancerResearch @BMSnews #Apexigen on this work. https://t.co/TawyR9v7u6

0

3

1

0

about 6 years ago

Some recent WF plots in PDAC 1L: #Apexigen APX005M (CD40)+GemAbrax +/- nivo, n=25 #AACR19 $CANTA CAN-04 (IL-1RAP)+GemAbrax, n=20 (press release) #CendR CEND-1 (iRGD)+GemAbrax, n=29 #ESMO20

BertrandBio's tweet photo. Some recent WF plots in PDAC 1L:

#Apexigen APX005M (CD40)+GemAbrax +/- nivo, n=25 #AACR19
$CANTA CAN-04 (IL-1RAP)+GemAbrax, n=20 (press release)
#CendR CEND-1 (iRGD)+GemAbrax, n=29 #ESMO20 https://t.co/dthgrUyjak

2

6

1

2

0

about 7 years ago

🔬 In March, the first results from a clinical trial (in partnership with @parkerici, @PennCancer, and #Apexigen) showed combining anti-CD-40, anti-PD-1, and chemotherapy shrank tumors in metastatic #PancreaticCancer patients. https://t.co/D4C96LMcLV #PCAM

0

11

3

0

over 7 years ago

Happy third birthday to our partner @parkici! Recently, we along with @parkerici, @bmsnews, and #Apexigen revealed promising results for combination therapy in pancreatic cancer at #AACR19: https://t.co/D4C96LMcLV #PICIbirthday

1

22

6

1

0

over 7 years ago

“These findings give us clues that new and innovative combination therapy can be effective against pancreatic cancer,” said Dr. Mark O’Hara of @PennMedicine in clinical trial study with CRI, @parkerici @bmsnews and #Apexigen. #pancsm https://t.co/0pENKyRoP1

0

4

3

0

over 7 years ago

#ICYMI: @sloan_kettering did a research recap from #AACR19 including our pancreatic cancer clincal trial with @parkerici @bmsnews and #Apexigen. #pancsm https://t.co/5X5BRvsg7h

0

7

1

0

over 7 years ago

Study of the CD40 Agonistic Monoclonal Antibody APX005M #AACR19 #Apexigen https://t.co/YgAFzN6n0i

0

2

0

over 7 years ago

Dr. Mark O’Hara of ⁦@PennMedicine⁩ presents interim analysis of phase 1b data on pancreatic cancer trial, organized by @CancerResearch Clinical Accelerator and @ParkerICI with @BMSNews and #Apexigen at #AACR19 #pancscm

CancerResearch's tweet photo. Dr. Mark O’Hara of ⁦@PennMedicine⁩ presents interim analysis of phase 1b data on pancreatic cancer trial, organized by @CancerResearch Clinical Accelerator and @ParkerICI with @BMSNews and #Apexigen at #AACR19 #pancscm https://t.co/lTkLtGde6u

0

8

1

0

over 7 years ago

Discussant Naing - APX005M #AACR19 #Apexigen

2

4

2

1

0

over 7 years ago

Discussant Naing - APX005M #AACR19 #Apexigen

1

2

0

over 7 years ago

Discussant Naing - APX005M #AACR19 #Apexigen

1

4

2

0

over 7 years ago

Phase Ib of CD40 agonistic mAb APX005M together w/ gemcitabine (Gem) & nab-paclitaxel (NP) w/ or w/o nivolumab (Nivo) in untreated metastatic PDAC patients #AACR19 #Apexigen Conclusion

BertrandBio's tweet photo. Phase Ib of CD40 agonistic mAb APX005M together w/ gemcitabine (Gem) & nab-paclitaxel (NP) w/ or w/o nivolumab (Nivo) in untreated metastatic PDAC patients #AACR19 #Apexigen

Conclusion https://t.co/JAkKllmA98

2

3

2

0

over 7 years ago

Phase Ib of CD40 agonistic mAb APX005M together w/ gemcitabine (Gem) & nab-paclitaxel (NP) w/ or w/o nivolumab (Nivo) in untreated metastatic PDAC patients #AACR19 #Apexigen immunoprofiling, ctDNA analysis

1

5

3

0

over 7 years ago

Phase Ib of CD40 agonistic mAb APX005M together w/ gemcitabine (Gem) & nab-paclitaxel (NP) w/ or w/o nivolumab (Nivo) in untreated metastatic PDAC patients #AACR19 #Apexigen impressive results! ORR, WF, swimmer, spider

1

9

1

0